Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Chem Sci ; 14(29): 7988-7998, 2023 Jul 26.
Artículo en Inglés | MEDLINE | ID: mdl-37502321

RESUMEN

Brain tumors are an important cause of suffering and death. Glioblastoma are the most frequent primary tumors of the central nervous system in adults. They are associated with a very poor prognosis, since only 10% of GBM patients survive 5 years after diagnosis. Medulloblastoma are the most frequent brain malignancies in childhood; they affect the cerebellum in children under 10 years of age in 75% of cases. The current multimodal treatment comes at the expense of serious and often long-lasting side effects. Herein, we propose the synthesis of a library of novel alkoxyamines as anticancer drug candidates. The most efficient molecule, ALK4, was selected based on its ability to inhibit both survival and migration of GBM and MB cells in 2D cultures and in 3D tumor spheroids. A fluorescent derivative was used to show the early cytosolic accumulation of ALK4 in tumor cells. Spontaneous homolysis of ALK4 led to the release of alkyl radicals, which triggered the generation of reactive oxygen species, fragmentation of the mitochondrial network and ultimately apoptosis. To control its homolytic process, the selected alkoxyamine was bioconjugated to a peptide selectively recognized by matrix metalloproteases. This bioconjugate, named ALK4-MMPp, successfully inhibited survival, proliferation, and invasion of GBM and MB tumor micromasses. We further developed innovative brain and cerebellum organotypic models to monitor treatment response over time. It confirmed that ALK4-MMPp significantly impaired tumor progression, while no significant damage was observed on normal brain tissue. Lastly, we showed that ALK4-MMPp was well-tolerated in vivo by zebrafish embryos. This study provides a new strategy to control the activation of alkoxyamines, and revealed the bioconjugate ALK4-MMPp bioconjugate as a good anticancer drug candidate.

2.
EBioMedicine ; 95: 104752, 2023 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-37572644

RESUMEN

BACKGROUND: Pharmacological synergisms are an attractive anticancer strategy. However, with more than 5000 approved-drugs and compounds in clinical development, identifying synergistic treatments represents a major challenge. METHODS: High-throughput screening was combined with target deconvolution and functional genomics to reveal targetable vulnerabilities in glioblastoma. The role of the top gene hit was investigated by RNA interference, transcriptomics and immunohistochemistry in glioblastoma patient samples. Drug combination screen using a custom-made library of 88 compounds in association with six inhibitors of the identified glioblastoma vulnerabilities was performed to unveil pharmacological synergisms. Glioblastoma 3D spheroid, organotypic ex vivo and syngeneic orthotopic mouse models were used to validate synergistic treatments. FINDINGS: Nine targetable vulnerabilities were identified in glioblastoma and the top gene hit RRM1 was validated as an independent prognostic factor. The associations of CHK1/MEK and AURKA/BET inhibitors were identified as the most potent amongst 528 tested pairwise drug combinations and their efficacy was validated in 3D spheroid models. The high synergism of AURKA/BET dual inhibition was confirmed in ex vivo and in vivo glioblastoma models, without detectable toxicity. INTERPRETATION: Our work provides strong pre-clinical evidence of the efficacy of AURKA/BET inhibitor combination in glioblastoma and opens new therapeutic avenues for this unmet medical need. Besides, we established the proof-of-concept of a stepwise approach aiming at exploiting drug poly-pharmacology to unveil druggable cancer vulnerabilities and to fast-track the identification of synergistic combinations against refractory cancers. FUNDING: This study was funded by institutional grants and charities.


Asunto(s)
Antineoplásicos , Glioblastoma , Animales , Ratones , Glioblastoma/tratamiento farmacológico , Glioblastoma/genética , Aurora Quinasa A , Sinergismo Farmacológico , Línea Celular Tumoral , Antineoplásicos/farmacología , Combinación de Medicamentos
3.
Cells ; 11(23)2022 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-36497191

RESUMEN

Medulloblastoma (MB) is the most common and aggressive paediatric brain tumour. Although the cure rate can be as high as 70%, current treatments (surgery, radio- and chemotherapy) excessively affect the patients' quality of life. Relapses cannot be controlled by conventional or targeted treatments and are usually fatal. The strong heterogeneity of the disease (four subgroups and several subtypes) is related to innate or acquired resistance to reference treatments. Therefore, more efficient and less-toxic therapies are needed. Here, we demonstrated the efficacy of a novel inhibitor (C29) of CXCR1/2 receptors for ELR+CXCL cytokines for the treatment of childhood MB. The correlation between ELR+CXCL/CXCR1/2 expression and patient survival was determined using the R2: Genomics Analysis and Visualization platform. In vitro efficacy of C29 was evaluated by its ability to inhibit proliferation, migration, invasion, and pseudo-vessel formation of MB cell lines sensitive or resistant to radiotherapy. The growth of experimental MB obtained by MB spheroids on organotypic mouse cerebellar slices was also assayed. ELR+CXCL/CXCR1/2 levels correlated with shorter survival. C29 inhibited proliferation, clone formation, CXCL8/CXCR1/2-dependent migration, invasion, and pseudo-vessel formation by sensitive and radioresistant MB cells. C29 reduced experimental growth of MB in the ex vivo organotypic mouse model and crossed the blood-brain barrier. Targeting CXCR1/2 represents a promising therapeutic strategy for the treatment of paediatric MB in first-line treatment or after relapse following conventional therapy.


Asunto(s)
Neoplasias Cerebelosas , Meduloblastoma , Animales , Ratones , Neoplasias Cerebelosas/tratamiento farmacológico , Meduloblastoma/tratamiento farmacológico , Recurrencia Local de Neoplasia , Calidad de Vida , Receptores de Interleucina-8A/metabolismo , Humanos , Niño
4.
EBioMedicine ; 82: 104149, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35816899

RESUMEN

BACKGROUND: Medulloblastoma is the most frequent brain malignancy of childhood. The current multimodal treatment comes at the expense of serious and often long-lasting side effects. Drug repurposing is a strategy to fast-track anti-cancer therapy with low toxicity. Here, we showed the ability of ß-blockers to potentiate radiotherapy in medulloblastoma with bad prognosis. METHODS: Medulloblastoma cell lines, patient-derived xenograft cells, 3D spheroids and an innovative cerebellar organotypic model were used to identify synergistic interactions between ß-blockers and ionising radiations. Gene expression profiles of ß-adrenergic receptors were analysed in medulloblastoma samples from 240 patients. Signaling pathways were explored by RT-qPCR, RNA interference, western blotting and RNA sequencing. Medulloblastoma cell bioenergetics were evaluated by measuring the oxygen consumption rate, the extracellular acidification rate and superoxide production. FINDINGS: Low concentrations of ß-blockers significantly potentiated clinically relevant radiation protocols. Although patient biopsies showed detectable expression of ß-adrenergic receptors, the ability of the repurposed drugs to potentiate ionising radiations did not result from the inhibition of the canonical signaling pathway. We highlighted that the efficacy of the combinatorial treatment relied on a metabolic catastrophe that deprives medulloblastoma cells of their adaptive bioenergetics capacities. This led to an overproduction of superoxide radicals and ultimately to an increase in ionising radiations-mediated DNA damages. INTERPRETATION: These data provide the evidence of the efficacy of ß-blockers as potentiators of radiotherapy in medulloblastoma, which may help improve the treatment and quality of life of children with high-risk brain tumours. FUNDING: This study was funded by institutional grants and charities.


Asunto(s)
Neoplasias Cerebelosas , Meduloblastoma , Niño , Metabolismo Energético , Humanos , Meduloblastoma/tratamiento farmacológico , Meduloblastoma/genética , Meduloblastoma/radioterapia , Calidad de Vida , Receptores Adrenérgicos beta/metabolismo , Receptores Adrenérgicos beta/uso terapéutico , Superóxidos
5.
Mem. Inst. Invest. Cienc. Salud (Impr.) ; 15(3): 19-26, Dic. 2017. tab, ilus
Artículo en Español | LILACS, BDNPAR | ID: biblio-907838

RESUMEN

Los lípidos de los alimentos cumplen un papel fundamental en nutrición humana. Con base en los potenciales efectos perjudiciales para la salud de las dietas altas en ácidos grasos trans (AGT) y la necesidad de contar con información sobre los niveles en alimentos de consumo local, se han investigado el contenido de AGT por espectrometría infrarroja, grasas totales y el porcentaje de AGT con respecto a lípidos totales en algunos alimentos procesados y materia prima grasa comercializados en cuatro ciudades de zonas urbanas del Paraguay. De los 28 tipos de alimentos analizados, el 84,7% contenía ≥0,2 gAGT/porción. Alrededor del 79% superó 5% de AGT totales en el contenido lipídico del alimento, nivel superior al recomendado actualmente por la OMS. En las muestras de materia prima grasa, se encontraron niveles excepcionalmente altos de AGT totales (77,6%) en comparación con los niveles recomendados (5%). Este trabajo presenta los primeros datos sobre el contenido de AGT en alimentos tradicionales de consumo en Paraguay como la chipa1, y destaca la importancia del control de la composición de los alimentos de venta local y sin etiquetado, así como la necesidad de apuntar a la reformulación de estos alimentos, con menores niveles de AGT con base en las recomendaciones nutricionales actuales a nivel mundial para la prevención de enfermedades cardiovasculares.


The food fats play a fundamental role in human nutrition. Based on the known adverse health effects of diets high in trans fatty acids (TFA) and the need for information on levels in food for local consumption, in this work we investigated the content of total lipids and total TFA in some processed foods and fat raw material commercialized in four cities in urban areas of Paraguay. Of the 28 types of foods analyzed, 84.7% contained ≥0.2 g TFA/serving. Approximately 79% exceeded 5% of total TFA in food fat, which is higher than those levelscurrently recommended by the WHO. In raw material fat samples, exceptionally high levels of total TFA were found (77.6%) compared to the recommended level (5%). This paper presents the first data on the content of TFA in traditional foods of consumption in Paraguay, as “chipa”, and highlights the importance of the control of the composition of the foods of local sale and without labeling, as well as the need to point to the reformulation of these foods, with lower levels of trans fatty acids based on the current nutritional recommendations worldwide for the prevention of cardiovascular diseases.


Asunto(s)
Manipulación de Alimentos , Lípidos , Ácidos Grasos trans , Espectroscopía Infrarroja Corta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA